APi Group Corporation logo APG - APi Group Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $52.50 DETAILS
HIGH: $55.00
LOW: $49.00
MEDIAN: $53.00
CONSENSUS: $52.50
UPSIDE: 26.11%

Stock News

APi Group Announces Participation in Upcoming Investor Conferences

APi Group Announces Participation in Upcoming Investor Conferences

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that its senior leadership team will be participating in a fireside chat during the William Blair 46th Annual Growth Stock Conference on Wednesday, June 3rd at 10:40 a.m. CT. A live webcast link and archived replay will be available in the “Events” area on the Investor Relations page of APi's website at APi Group Investor Relations - Events. Interested parties should check the Compan.

May 20, 2026 03:30 AM • businesswire.com
APi Group Announces Closing of Previously Announced Financing Transactions

APi Group Announces Closing of Previously Announced Financing Transactions

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the closing of two previously announced financing transactions: a private offering of $500 million in aggregate principal amount of 5.75% senior notes due 2034, and an amendment to the Company's existing credit agreement (the "Amendment"), which extends the maturity of the Company's Term Loan B facility to 2033 and upsizes and extends the Company's revolving credit facility to $1.0 b.

May 15, 2026 03:30 AM • businesswire.com
APi Group Announces Pricing of $500 Million Senior Notes

APi Group Announces Pricing of $500 Million Senior Notes

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the pricing of the previously announced private offering by APi Group DE, Inc. ("APi DE"), a wholly owned subsidiary of the Company, of $500 million in aggregate principal amount of 5.75% senior notes due 2034 (the "Notes") at an offering price of 100% of the principal amount thereof. The Notes will be senior unsecured obligations of APi DE and will be fully and unconditionally guara.

May 07, 2026 02:00 PM • businesswire.com
APi Group Announces Launch of $500 Million Senior Notes Offering and Intent to Amend and Extend Existing Credit Agreement

APi Group Announces Launch of $500 Million Senior Notes Offering and Intent to Amend and Extend Existing Credit Agreement

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the launch of a $500 million senior unsecured notes offering (the "Notes"), subject to market and other customary conditions. The Notes will be senior unsecured obligations of APi Group DE, Inc. ("APi DE"), a wholly owned subsidiary of the Company, and will be fully and unconditionally guaranteed on a senior unsecured basis by the Company and certain of the Company's existing and fut.

May 07, 2026 04:00 AM • businesswire.com
APi Group Reports First Quarter 2026 Financial Results

APi Group Reports First Quarter 2026 Financial Results

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today reported its financial results for the three months ended March 31, 2026. Russ Becker, APi's President and Chief Executive Officer, stated: "We are off to a strong start in 2026, delivering 10% organic net revenue growth and expanding adjusted EBITDA margins by 70 basis points year over year, with strength across both our Safety Services and Specialty Services segments. At the same time, we co.

Apr 30, 2026 03:30 AM • businesswire.com
APi Group to Acquire Onyx-Fire Protection Services Inc.

APi Group to Acquire Onyx-Fire Protection Services Inc.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that it has entered into a definitive agreement to acquire Onyx-Fire Protection Services Inc. (“Onyx-Fire”), an inspection-first provider of fire and life safety services in Canada, from funds managed by Blackstone Tactical Opportunities (“Blackstone”). The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including receipt of re.

Apr 23, 2026 03:30 AM • businesswire.com
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstracts selected for poster presentations, these data highlight the global innovation and clinical value of Ascentage Pharma's portfolio, inclusive of Olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China; Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor; and Alrizomadlin (APG-115), an MDM2-p53 inhibitor.

Apr 21, 2026 04:00 PM • globenewswire.com
APi Group Announces the Acquisition of Wtech Fire Group

APi Group Announces the Acquisition of Wtech Fire Group

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that it has entered into a definitive agreement to acquire Wtech Fire Group (“Wtech”), a comprehensive provider of fire protection, suppression, and detection solutions across Europe. The transaction is expected to close in the second half of 2026, subject to customary closing conditions, including receipt of required regulatory approvals. Wtech is headquartered in Ireland and serves.

Apr 17, 2026 03:30 AM • businesswire.com
APi Group Confirms Date of First Quarter 2026 Earnings Release

APi Group Confirms Date of First Quarter 2026 Earnings Release

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi”) announced today that it intends to release its financial results for the three months ended March 31, 2026, before the market opens on Thursday, April 30, 2026. First Quarter Earnings Conference Call: APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, April 30, 2026. Participants on the call will include Russell A. Becker, President and Chief Exe.

Apr 14, 2026 03:30 AM • businesswire.com
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients maintained vIGA 0/1 Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart

Mar 23, 2026 02:30 AM • globenewswire.com
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m.

Mar 22, 2026 03:51 PM • globenewswire.com

Price Targets